华健未来-B

开始申购 2026-06-12

未上市

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
- 【IPO速递】宁德、高瓴加持！“钴王”旗下华创新材收入暴增却造血艰难
  港股解码 · 06-15 16:46
  【IPO速递】宁德、高瓴加持！“钴王”旗下华创新材收入暴增却造血艰难
- 华健未来（成都）科技股份有限公司首发13,600,000股H股，发售价每股81.80港元
  公告速递 · 06-12
  华健未来（成都）科技股份有限公司首发13,600,000股H股，发售价每股81.80港元
公司概况
公司名称
华健未来－Ｂ
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
- -
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
华健未来由多位博士共同创立,主要从事针对肿瘤,自身免疫系统疾病和代谢系统疾病创新药物的研发和生产
- 06-12
  股份发售
  全球发售
  全球发售

2026-06-12

招股说明书查看招股说明书

2026-06-12

发行信息

价格范围
81.800HKD
发售规模
73.60M
市值
6.02B
最小购买量
100
杠杆率
待定

2026-06-17

已休市

发行价格
待定

2026-06-22

中签日

抽签率
待定

2026-06-23

上市

热议股票

{"pagemeta":{"title":"华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华健未来-B(06132)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华健未来-B,06132,华健未来-B股票,华健未来-B股票老虎,华健未来-B股票老虎国际,华健未来-B行情,华健未来-B股票行情,华健未来-B股价,华健未来-B股市,华健未来-B股票价格,华健未来-B股票交易,华健未来-B股票购买,华健未来-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华健未来-B(06132)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"news","symbol":"06132","data":{"stockData":{"symbol":"06132","market":"HK","secType":"STK","nameCN":"华健未来-B","latestPrice":81.8,"timestamp":1781676462700,"preClose":81.8,"halted":9,"volume":0,"delay":0,"changeRate":0,"floatShares":73599600,"shares":73599605,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"06-17 14:07:42","open":81.8,"high":81.8,"low":81.8,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.127,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782178200000},"marketStatusCode":8,"adr":0,"listingDate":1782144000000,"exchange":"SEHK","adjPreClose":81.8,"openAndCloseTimeList":[[1781659800000,1781668800000],[1781672400000,1781683200000]],"volumeRatio":0,"ipoDetail":{"name":"华健未来－Ｂ","exchange":"SEHK","listingDate":"2026-06-23","sharesOutstanding":73599605,"sharesFloat":73599605,"offerAmount":13600000,"priceRange":"81.800","market":"HK","openProspectusDate":"2026-06-12","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0612/2026061200084_c.pdf","purchaseBeginDate":"2026-06-12","purchaseEndDate":"2026-06-17","winningDate":"2026-06-22","currency":"HKD","minPurchaseQuantity":100,"peRate":-40.33,"use":"1、约80.6%或821.3百万港元将用于正在进行及计划中的管线产品临床研究及开发活动提供资金；\n2、约9.4%或95.6百万港元将用于提升研发平台以加强在免疫学、代谢和肿瘤学领域的创新管线，并开拓且开发新临床前药物以加强目前的治疗选项；\n3、约5.0%或50.9百万港元将用于逐步建立商业化团队，并随着候选药物接近商业化而扩大团队，确保产品上市时能有效拓展市场并提供支援；\n4、约5.0%或50.9百万港元将用于一般业务运营及营运资金。","industryId":"204005","industryName":"医疗保健","business":"公司由致力研发自身免疫、代谢及肿瘤学疾病的疗法的行业专家团队创立，透过识别临床需求及从预期结果倒推进行逆向工作，致力提供改良治疗解决方案。","subscribed":1166.96,"marketCap":6020000000,"minimumCapital":8262.49,"overAllotment":true,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,150000,200000,250000,300000,350000,400000,450000,500000,600000,680000","issueRatio":0.1,"offeringMechanism":"B"},"greyMarketDetail":{"greyDate":"2026-06-22","greyDateTimestamp":1782057600000,"greyOpeningTime":1782116100000,"greyClosingTime":1782124200000,"showGreyQuote":false,"openProspectusDate":"2026-06-12","listingDate":"2026-06-23"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":null,"newsData":{"listData":[{"id":"2643224753","title":"【IPO速递】宁德、高瓴加持！“钴王”旗下华创新材收入暴增却造血艰难","url":"https://stock-news.laohu8.com/highlight/detail?id=2643224753","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643224753?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:46","pubTimestamp":1781513160,"startTime":"0","endTime":"0","summary":"华创新材的亮点与隐忧泾渭分明。2023至2025年，华创新材收入从43.62亿元增至86.30亿元，两年近乎翻倍，增长势头迅猛。比利润更严峻的是现金流问题，2023至2025年，华创新材的经营现金流处于持续净流出状态，2025年净流出高达38.22亿元，收入账面亮眼，主业却持续“失血”。此外，华创新材为典型家族控制企业，实控人为陈雪华夫妇。二人通过控股股东华友控股直接持股58.17%，叠加关联持股平台铜陵创安汇等，合计掌控公司61.72%的股权，公司控制权高度集中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s/C1ZkEXoEbT3F7QJmw2iDkQ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK0132","LU0359201885.HKD","BK0188","06132","BK0233","LU1152091168.USD","03677","300014","BK0070","LU1580142542.USD","LU0469268626.HKD","LU1008478684.HKD","LU1934453819.USD","LU1781817850.SGD","SGXZ81163826.USD","06067","03750","BK0224","BK0155","BK1116","LU0359202008.SGD","LU0880133367.SGD","LU1993786604.SGD","BK0196","LU1960683339.HKD","603799","LU1152091754.HKD","LU1979443071.USD","LU0359201612.USD","300750","LU1808992512.USD","LU1023057109.AUD","BK0077","BK1610","BK0201","LU0067412154.USD","EVS.SI","BK0182","SGXZ49509284.SGD","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149230137","title":"华健未来（成都）科技股份有限公司首发13,600,000股H股，发售价每股81.80港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149230137","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149230137?lang=zh_cn&edition=full","pubTime":"2026-06-12 07:30","pubTimestamp":1781220652,"startTime":"0","endTime":"0","summary":"华健未来（成都）科技股份有限公司成立于2017年，主要从事自身免疫、代谢和肿瘤等领域创新疗法的研究与开发，现有核心产品管线包括HJ787、HJ178、HJ891等，另有HJ356、HJ093、HJ198、HJ086等多款临床前候选药物。截至2024年12月31日止年度，收入约为人民币1,800千元，研发开支约为人民币74,973千元，年内亏损及全面亏损总额约为人民币202,317千元。公司本次全球发售总数为13,600,000股H股，发售价为每股81.80港元，香港公开发售部分为1,360,000股，国际配售部分为12,240,000股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"华健未来（成都）科技股份有限公司首发13,600,000股H股，发售价每股81.80港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":1}],"currentPage":1,"bottom":true},"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"21385354","market":"hk","labels":[],"media":"港交所","original_id":"N.HK36r21Jopk9","pdf_url":"https://static.tigerbbs.com/7e6ef2d417654179ad88f97a2dde7030","pub_time":1781219700000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"全球发售","symbol":"06132","title":"全球发售","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0612/2026061200084_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2026-06-12 07:15","pubTimestamp":1781219700,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":-0.0566},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.0394},{"period":"1year","weight":0.018},{"period":"ytd","weight":-0.0443}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华健未来由多位博士共同创立,主要从事针对肿瘤,自身免疫系统疾病和代谢系统疾病创新药物的研发和生产","exchange":"SEHK","name":"华健未来-B","nameEN":"HJ SCIENCE-B"},"aProfile":null}}}